Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 6/6

ABSTRACT: During discovery and development of protein-based drugs, extensive animal testing is required for preclinical analysis of pharmacokinetics, tissue biodistribution, toxicity, etc. Generally, several animals are required for testing a single drug. We show that the use of genetically encoded peptide barcodes, called flycodes, allows for the simultaneous preclinical assessment of dozens of antibodies from single cassette-dosed mice. Datasets: 1. comparison of flycodes vs. unique endogenous tryptic peptides for antibody identification 2. antibody PK, cassette dose A (high dose) 3. antibody PK, cassette dose B (low dose) 4. antibody tumor/organ biodistribution 5. Dar-SB thermostability 6. Dar-SB PK

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Synthetic Construct Mus Musculus (mouse)

TISSUE(S): Blood Plasma

SUBMITTER: Justin Walter

LAB HEAD: Markus Seeger

PROVIDER: PXD036668 | Pride | 2025-02-26

REPOSITORIES: pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	191216_pool_ID-peptide-export_for-mascot.mgf	Mgf
	20191209_002_S210018_SHL3_1_pool_m1-3_t0_15min_A.raw	Raw
	20191209_003_S210019_SHL3_2_pool_m1-3_t1_30min_A.raw	Raw
	20191209_004_S210020_SHL3_3_pool_m1-3_t2_3h_A.raw	Raw
	20191209_005_S210021_SHL3_4_pool_m1-3_t3_1d_A.raw	Raw

Items per page:

1 - 5 of 31

Similar Datasets

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 5/6

Project description:During discovery and development of protein-based drugs, extensive animal testing is required for preclinical analysis of pharmacokinetics, tissue biodistribution, toxicity, etc. Generally, several animals are required for testing a single drug. We show that the use of genetically encoded peptide barcodes, called flycodes, allows for the simultaneous preclinical assessment of dozens of antibodies from single cassette-dosed mice. Datasets: 1. comparison of flycodes vs. unique endogenous tryptic peptides for antibody identification 2. antibody PK, cassette dose A (high dose) 3. antibody PK, cassette dose B (low dose) 4. antibody tumor/organ biodistribution 5. Dar-SB thermostability 6. Dar-SB PK

2025-02-26 | PXD036666 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 3/6

2025-02-26 | PXD036661 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 2/6

2025-02-26 | PXD036734 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 4/6

2025-02-26 | PXD036662 | Pride

Flycodes enable preclinical analysis of dozens of antibodies using single cassette-dosed mice. Dataset 1/6

2025-02-26 | PXD036658 | Pride

Engineered Peptide Barcodes for Binding Protein Generation

Project description:Binding protein generation relies on laborious screening cascades that process candidate molecules individually. To break with this paradigm, we developed NestLink, a binder selection and identification technology able to biophysically characterize thousands of library members at once without handling individual clones at any stage of the process. NestLink builds on genetically fused barcoding peptides, termed flycodes, which are designed for maximal detectability by mass spectrometry and serve as unique molecular identifiers for accurate deep sequencing. We applied NestLink to overcome current limitations of binder generation. Rare binders against an integral membrane protein were identified directly in the cellular environment of a human pathogen. Hundreds of binder candidates were simultaneously ranked according to kinetic parameters. Adverse effects of target immobilization were overcome by selecting nanobodies against an ABC transporter entirely in solution. NestLink may provide a basis for the selection of tailored binder characteristics directly in tissues or in living organisms

2019-01-15 | PXD009301 | Pride

Anopheles arabiensis Zanzibar

Project description:The transcriptional profile of pyrethroid resistant Anopheles arabiensis from Zanzibar. Anopheles arabiensis from Pemba Island, exposed (Survivors) and non-exposed (Pemba) to a discriminating dose of the pyrethroid lambda-cyhalothrin were compared to two insecticide susceptible strains from Zanzibar island (Unguja) and Dar es Salaam (Dar).

2014-01-01 | E-MTAB-2074 | biostudies-arrayexpress

Pre-clinical proof of principle for orally delivered Th17 antagonist miniproteins

Project description:Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell signaling in vitro and are extremely stable, enabling oral administration and low-cost manufacturing. The orally administered IL-23R minibinder shows efficacy better than a clinical anti-IL-23 antibody in mouse colitis and has a favorable pharmacokinetics (PK) and biodistribution profile in rats. This work demonstrates that orally administered de novo-designed minibinders can reach a therapeutic target past the gut epithelial barrier. With high potency, gut stability, and straightforward manufacturability, de novo-designed minibinders are a promising modality for oral biologics.

2024-06-26 | GSE263250 | GEO

A Biodistribution Study of OTV vs. ASO by Intravenous or Intrathecal Administration in Cynomolgus Monkeys

Project description:The objective of this study is to evaluate ASO biodistribution and pharmacodynamic response following intravenous delivery of conjugated OTV, which utilizes transferrin-receptor binding to deliver ASO, vs. intrathecal delivery of naked ASO in cynomolgus monkeys, the current gold standard for ASO delivery. Three groups were included for comparison: 1) Negative control cohort = Four biweekly intravenous doses of saline (n=3); 2) IT cohort = Single intrathecal dose of 4mg MALAT1 ASO (n=3); 3)  OTV multi dose cohort = Four biweekly intravenous doses of 30mpk OTV:MALAT1 (n=3). Tissues were collected two weeks after the final dose to allow sufficient time for target knockdown. Brain, spinal cord, and peripheral tissues were dissected and frozen for molecular analysis. Compared to an intrathecal injection of ASO, systemic administration of OTV resulted in significantly more homogenous biodistribution of ASO in the central nervous system as measured by a probe-based hybridization assay as well as staining with an anti-ASO antibody. One potential consequence of heterogeneous ASO distribution is heterogeneous target knockdown throughout the CNS. We observed more consistent target knockdown throughout the cortex, subcortical areas, and spinal cord of monkeys dosed peripherally with OTV. By contrast, monkeys dosed intrathecally with naked ASO showed much more knockdown in the spinal cord compared to the brian, consistent with ASO distribution.

2024-02-12 | GSE208114 | GEO

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Project description:This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen for metastatic disease. Primary study objectives were to determine the influence of the CS-1008 dose on the biodistribution, pharmacokinetics (PK) and tumor uptake of radiolabeled CS-1008 following a single infusion and following continuous sequential doses of CS-1008. Secondary objectives were to evaluate changes in tumor metabolism, antitumor response, and changes in serum apoptosis biomarkers and tumor response markers following treatment with CS-1008.

| 2096559 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data